SCHEMBL4433121

SCHEMBL4433121

O=C(O)c1cccn(Cc2ccc3ccccc3c2)c1=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 2/20 0.52
BRD2 P25440 1/20 0.52
BRD3 Q15059 1/20 0.52
BRDT Q58F21 1/20 0.52
SMN1; SMN2 Q16637 6/20 0.51
MAPT P10636 1/20 0.51
RAB9A P51151 1/20 0.51
KDM4E B2RXH2 3/20 0.46
HTT P42858 2/20 0.46
TBXAS1 P24557 1/20 0.46
ALDH1A1 P00352 3/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
CNR1 P21554 3/20 0.45
CNR2 P34972 3/20 0.45
ATM Q13315 1/20 0.44
POLB P06746 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
TP53 P04637 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4986388 0.88 SMN1; SMN2 (0.54) BRD4BRD2BRD3BRDTSMN1; SMN2
SCHEMBL4431812 0.86 MAPT (0.54) BRD4BRD2BRD3BRDTMAPT
SCHEMBL4425995 0.84 MAPT (0.56) BRD4BRD2BRD3BRDTSMN1; SMN2
SCHEMBL1137531 0.84 BRD4 (0.70) BRD4BRD2BRD3BRDTSMN1; SMN2
Hydrochloric Acid SCHEMBL11454825 0.82 BRD4 (0.68) BRD4BRD2BRD3BRDTSMN1; SMN2
SCHEMBL4993019 0.81 BRD4 (0.59) BRD4BRD2BRD3BRDTSMN1; SMN2
SCHEMBL4992892 0.81 BRD4 (0.68) BRD4BRD2BRD3BRDTSMN1; SMN2
SCHEMBL9022276 0.81 CNR2 (0.47) KDM4EMEN1KMT2ACNR1CNR2
SCHEMBL3353651 0.81 KDM4E (0.63) BRD4BRD2BRD3BRDTSMN1; SMN2
SCHEMBL4990678 0.81 BRD4 (0.59) BRD4BRD2BRD3BRDTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2125739-A1 MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF ENCYSIVE PHARMACEUTICALS, INC. (US) 2009-12-02 EP disclosed
US-20080188528-A1 Modulators of C3a receptor and methods of use thereof ENCYSIVE PHARMACEUTICALS, INC. 2008-08-07 US disclosed
US-20080188528-A1 Modulators of C3a receptor and methods of use thereof ENCYSIVE PHARMACEUTICALS, INC. 2008-08-07 US disclosed
US-20080188528-A1 Modulators of C3a receptor and methods of use thereof ENCYSIVE PHARMACEUTICALS, INC. 2008-08-07 US disclosed
WO-2008079371-A1 MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF ENCYSIVE PHARMACEUTICALS, INC. (US) 2008-07-03 WO disclosed
WO-2008079371-A1 MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF ENCYSIVE PHARMACEUTICALS, INC. (US) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188528-A1 Modulators of C3a receptor and methods of use thereof C3AR1, C5, C5AR1 BRD4 2776/4885BRD2 4008/4885BRD3 3120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.